Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 multicenter, randomized, double-blind, placebo-controlled trial to evaluate the safety and efficacy of IM-101, a novel complement C5 inhibitor, for the treatment of Myasthenia Gravis

Next Previous
Trial Profile

A Phase 2 multicenter, randomized, double-blind, placebo-controlled trial to evaluate the safety and efficacy of IM-101, a novel complement C5 inhibitor, for the treatment of Myasthenia Gravis

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 05 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IM-101 (Primary)
  • Indications Myasthenia gravis
  • Focus Therapeutic Use

Most Recent Events

  • 05 Jun 2025 New trial record
  • 02 Jun 2025 According to a ImmunAbs media release,company announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) application to initiate a Phase 2 clinical trial evaluating the safety and efficacy of IM-101, a novel complement C5 inhibitor, for the treatment of Myasthenia Gravis.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top